UB Paderborn / Katalog / Suche / in CDI

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example

Diabetes, obesity & metabolism, 2019-10, Vol.21 (10), p.2203-2210

2019

Link zum Volltext

Verfügbarkeit prüfen

Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease

The New England journal of medicine, 2008-10, Vol.359 (18), p.1897-1908

2008

Link zum Volltext

Verfügbarkeit prüfen

The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach

PLoS medicine, 2012-05, Vol.9 (5), p.e1001212-e1001212

2012

Link zum Volltext

Verfügbarkeit prüfen

Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes

Diabetes, obesity & metabolism, 2018-09, Vol.20 (9), p.2238-2245

2018

Link zum Volltext

Verfügbarkeit prüfen

C-Reactive Protein and the Risk of Cancer: A Mendelian Randomization Study

JNCI : Journal of the National Cancer Institute, 2010-02, Vol.102 (3), p.202-206

2010

Link zum Volltext

Verfügbarkeit prüfen

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

Diabetes therapy, 2018-08, Vol.9 (4), p.1533-1547

2018

Link zum Volltext

Verfügbarkeit prüfen

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial

Journal of diabetes investigation, 2017-03, Vol.8 (2), p.210-217

2017

Link zum Volltext

Verfügbarkeit prüfen

Using genetic loci to understand the relationship between adiposity and psychological distress: a Mendelian Randomization study in the Copenhagen General Population Study of 53 221 adults

Journal of internal medicine, 2011-05, Vol.269 (5), p.525-537

2011

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial

Diabetes, obesity & metabolism, 2018-05, Vol.20 (5), p.1202-1212

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes

Diabetes, obesity & metabolism, 2018-02, Vol.20 (2), p.378-388

2018

Link zum Volltext

Verfügbarkeit prüfen

A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin

Diabetes care, 2018-09, Vol.41 (9), p.1926-1937

2018

Link zum Volltext

Verfügbarkeit prüfen

SAT-201 Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests

Journal of hepatology, 2024-06, Vol.80, p.S606-S607

2024

Link zum Volltext

Verfügbarkeit prüfen

Does Elevated C-Reactive Protein Increase Atrial Fibrillation Risk?

Journal of the American College of Cardiology, 2010-08, Vol.56 (10), p.789-795

2010

Link zum Volltext

Verfügbarkeit prüfen

C-reactive protein and all-cause mortality—the Copenhagen City Heart Study

European heart journal, 2010-07, Vol.31 (13), p.1624-1632

2010

Link zum Volltext

Verfügbarkeit prüfen

Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme

Diabetes, obesity & metabolism, 2018-10, Vol.20 (10), p.2426-2434

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials

The Lancet (British edition), 2011-08, Vol.378 (9791), p.584-594

2011

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects

Advances in therapy, 2018-04, Vol.35 (4), p.531-544

2018

Link zum Volltext

Verfügbarkeit prüfen

C-reactive protein and risk of venous thromboembolism in the general population

Arteriosclerosis, thrombosis, and vascular biology, 2010-08, Vol.30 (8), p.1672

2010

Link zum Volltext

Verfügbarkeit prüfen

Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls

European journal of epidemiology, 2013-08, Vol.28 (8), p.621-647

2013

Link zum Volltext

Verfügbarkeit prüfen

Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population

Journal of the American College of Cardiology, 2010-08, Vol.56 (10), p.789-795

2010

Link zum Volltext

Verfügbarkeit prüfen

Cover Image, Volume 20, Issue 2

Diabetes, obesity & metabolism, 2018-02, Vol.20 (2)

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in J apanese people with type 2 diabetes

Diabetes, obesity & metabolism, 2018-02, Vol.20 (2), p.378-388

2018

Link zum Volltext

Verfügbarkeit prüfen

Greater Combined Reductions in Hba1C ≥1.0% and Weight ≥5.0% with Semaglutide Versus Comparators in type 2 Diabetes

Endocrine practice, 2019-06, Vol.25 (6), p.589-597

2019

Link zum Volltext

Verfügbarkeit prüfen

Increased Baseline C-Reactive Protein Concentrations Are Associated with Increased Risk of Infections: Results from 2 Large Danish Population Cohorts

Clinical chemistry (Baltimore, Md.), 2016-02, Vol.62 (2), p.335-342

2016

Link zum Volltext

Verfügbarkeit prüfen

Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: Cross‐sectional and prospective studies and meta‐analyses of 75,000 cases and 93,000 controls

International journal of cancer, 2011-02, Vol.128 (3), p.644-652

2011

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example

Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease

The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach

Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes

C-Reactive Protein and the Risk of Cancer: A Mendelian Randomization Study

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial

Using genetic loci to understand the relationship between adiposity and psychological distress: a Mendelian Randomization study in the Copenhagen General Population Study of 53 221 adults

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes

A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin

SAT-201 Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests

Does Elevated C-Reactive Protein Increase Atrial Fibrillation Risk?

C-reactive protein and all-cause mortality—the Copenhagen City Heart Study

Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme

Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects

C-reactive protein and risk of venous thromboembolism in the general population

Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls

Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population

Cover Image, Volume 20, Issue 2

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in J apanese people with type 2 diabetes

Greater Combined Reductions in Hba1C ≥1.0% and Weight ≥5.0% with Semaglutide Versus Comparators in type 2 Diabetes

Increased Baseline C-Reactive Protein Concentrations Are Associated with Increased Risk of Infections: Results from 2 Large Danish Population Cohorts

Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: Cross‐sectional and prospective studies and meta‐analyses of 75,000 cases and 93,000 controls

Suchergebnisse filtern